Gilead Sciences (GILD)
(Delayed Data from NSDQ)
$73.78 USD
-0.56 (-0.75%)
Updated Aug 16, 2024 04:00 PM ET
After-Market: $73.77 -0.01 (-0.01%) 5:28 PM ET
3-Hold of 5 3
B Value B Growth B Momentum A VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$73.78 USD
-0.56 (-0.75%)
Updated Aug 16, 2024 04:00 PM ET
After-Market: $73.77 -0.01 (-0.01%) 5:28 PM ET
3-Hold of 5 3
B Value B Growth B Momentum A VGM
Zacks News
Closing the Books on Q1 Earnings Season
by Sheraz Mian
What we saw this earnings season was anemic growth and continuation of the negative guidance.
Another Weak Earnings Season Coming to an End
by Sheraz Mian
What we saw this earnings season was anemic growth and continuation of the negative guidance.
Q1 Earnings Season Coming to an End
by Sheraz Mian
What we saw this earnings season was anemic growth and continuation of the negative guidance.
Q1 Earnings Season in Final Stretch
by Sheraz Mian
Earnings growth has been hard to come by for some time.
Q2 Earnings Estimates Coming Down
by Sheraz Mian
Earnings growth has been hard to come by for some time.
An Improving, But Still Weak Earnings Picture
by Sheraz Mian
There is still plenty that is disappointing about the Q1 earnings.